Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome
- PMID: 20047153
Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome
Abstract
Infusion reactions and cytokine release syndrome (CRS) are an emerging issue in drug development and are of particular importance with the development of new therapeutic proteins. Increasing concerns regarding patient safety require a better understanding of the mechanism involved and the development of novel methods for preventing and predicting such reactions and CRS. This review discusses developments during the past few years in understanding the mechanisms that cause infusion reactions and CRS, advances in approaches to prevent CRS, the reason why preclinical animal models are unreliable predictors of CRS, and new developments in the design and analysis of in vitro screening systems for the prediction of CRS.
Similar articles
-
Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29. Int Immunopharmacol. 2011. PMID: 21689786
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Immune-mediated adverse drug reactions.Chem Res Toxicol. 2009 Jan;22(1):24-34. doi: 10.1021/tx800389u. Chem Res Toxicol. 2009. PMID: 19149477 Review.
-
Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction.J Immunotoxicol. 2008 Jan;5(1):11-5. doi: 10.1080/15476910801897433. J Immunotoxicol. 2008. PMID: 18382853 Review.
-
Monoclonal antibody-induced cytokine-release syndrome.Expert Rev Clin Immunol. 2009 Sep;5(5):499-521. doi: 10.1586/eci.09.31. Expert Rev Clin Immunol. 2009. PMID: 20477639
Cited by
-
Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE).J Control Release. 2022 Apr;344:50-61. doi: 10.1016/j.jconrel.2021.12.027. Epub 2021 Dec 23. J Control Release. 2022. PMID: 34953981 Free PMC article.
-
Clinical development methodology for infusion-related reactions with monoclonal antibodies.Clin Transl Immunology. 2015 Jul 17;4(7):e39. doi: 10.1038/cti.2015.14. eCollection 2015 Jul. Clin Transl Immunology. 2015. PMID: 26246897 Free PMC article. Review.
-
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Biomark Res. 2018 Jan 22;6:4. doi: 10.1186/s40364-018-0116-0. eCollection 2018. Biomark Res. 2018. PMID: 29387417 Free PMC article. Review.
-
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Oncoimmunology. 2017. PMID: 29209572 Free PMC article. Review.
-
Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.Commun Biol. 2018 Sep 14;1:146. doi: 10.1038/s42003-018-0149-9. eCollection 2018. Commun Biol. 2018. PMID: 30272022 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous